FP7 INTERNATIONAL SYMPOSIUM ON INFLAMMATORY BOWEL DISEASES (IPODD ANNUAL MEETING, ROME, 13-16 April 2011)
13 April 2011 - 16 April 2011
Austria
The IPODD annual meeting (Rome, April 13-16) will discuss innovative strategies for studying and treating Inflammatory Bowel Diseases (IBDs).
IPODD (www.ipodd.eu) is a 3-years FP7 consortium launched in 2008 for research on IBDs.
IBDs are chronic disorders of the gastrointestinal tract that include CROHN's DISEASE and ULCERATIVE COLITIS. They affect 1-5 people out of 1000 in Europe.
IBDs are an important cause of disability and morbidity, interfering with the quality of life of thousands people for many years.
The program includes:
a SUMMER SCHOOL FOR YOUNG RESEARCHERS (April 13th);
a PUBLIC SYMPOSIUM (April 15th) featuring keynote speakers from the UK, Germany, Israel, Canada, France, New Zealand, USA and Italy.
Goals:
- To discuss and disseminate the latest findings from IPODD;
- To Review the most promising avenues in IBD research, including work on proteases, probiotic intervention and gene-diet interactions.
Representatives from the European Federation of Crohn's and Colitis Associations (EFCCA) will also bring the patients' angle on IBDs.
Details about the IPODD symposium are available at http://goo.gl/MN2lU(opens in new window)
-------
IPODD (an acronym for "Intestinal Proteases: Opportunity for Drug Discovery”) has put together the expertise of 13 research teams across 7 countries (1) coordinated by Prof. David Grundy at the University of Sheffield. The project was funded by the EU seventh framework program (FP7) with €3 million and will expire in July 2011.
IPODD (www.ipodd.eu) is a 3-years FP7 consortium launched in 2008 for research on IBDs.
IBDs are chronic disorders of the gastrointestinal tract that include CROHN's DISEASE and ULCERATIVE COLITIS. They affect 1-5 people out of 1000 in Europe.
IBDs are an important cause of disability and morbidity, interfering with the quality of life of thousands people for many years.
The program includes:
a SUMMER SCHOOL FOR YOUNG RESEARCHERS (April 13th);
a PUBLIC SYMPOSIUM (April 15th) featuring keynote speakers from the UK, Germany, Israel, Canada, France, New Zealand, USA and Italy.
Goals:
- To discuss and disseminate the latest findings from IPODD;
- To Review the most promising avenues in IBD research, including work on proteases, probiotic intervention and gene-diet interactions.
Representatives from the European Federation of Crohn's and Colitis Associations (EFCCA) will also bring the patients' angle on IBDs.
Details about the IPODD symposium are available at http://goo.gl/MN2lU(opens in new window)
-------
IPODD (an acronym for "Intestinal Proteases: Opportunity for Drug Discovery”) has put together the expertise of 13 research teams across 7 countries (1) coordinated by Prof. David Grundy at the University of Sheffield. The project was funded by the EU seventh framework program (FP7) with €3 million and will expire in July 2011.